Evidence map›Paper›PMID 17442096›Full record

ArticleRetrovirology2007

Retroviral activation of the mir-106a microRNA cistron in T lymphoma.

Amy M Lum, Bruce B Wang, Lauri Li, Namitha Channa, Gabor Bartha, Matthias Wabl

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2012
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. MicroRNAs in cancer.Annual review of pathology · 2009
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Amy M LumPicobella, L.L.C., Burlingame, CA, 94010, USA. amy@picobella.com
Bruce B Wang
Lauri Li
Namitha Channa
Gabor Bartha
Matthias Wabl
Collaborative Drug Discovery (United States) · USUniversity of California, San Francisco · US

Funding

Tumor Suppressors in LymphocytesR01CA100266 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WABL, MATTHIAS R · 2006 to 2008
$802k
NCI NIH HHS CA100266NCI NIH HHS R01 CA100266
6 · The paper itself

Abstract

Retroviral insertion into a host genome is a powerful tool not only for the discovery of cancer genes, but also for the discovery of potential oncogenic noncoding RNAs. In a large-scale mouse T lymphocyte tumor screen we found a high density of integrations upstream of the mir-106a microRNA cistron. In tumors containing an integration, the primary transcript encoding the mir-106a cistron was overexpressed five to 20-fold compared with that of control tumors; concomitantly, the mature mir-106a and mir-363 microRNAs were highly overexpressed as well. These findings suggest the mir-106a cistron plays an important role in T cell tumorigenesis.

Indexed as

Gene Expression RegulationTranscription, GeneticAnimalsDisease Models, AnimalFemaleGenesLymphoma, T-CellMaleMiceMicroRNAsRecombination, GeneticRetroviridaeMicroRNAs

Identifiers

PMID17442096
PMCPMC1794537
OpenAlexW1597595254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.